Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety and efficacy profile of different treatment regimens of Ruxolitinib (INCB018424) administered to two groups of patients; those with polycythemia vera (PV) and those with essential thrombocythemia (ET). Patients in each group were refractory to hydroxyurea or for whom hydroxyurea is contraindicated.


Clinical Trial Description

The study consisted of a 2-stage design, which included a dose-ranging phase (during which patients received treatment at their randomized dose) and an expansion phase (after adjustment of dose/regimen to achieve an optimal balance of efficacy and safety). During the dose-ranging phase, patients in each disease group (PV or ET) were randomly assigned in a 1:1:1 ratio independent of each other to receive 1 of 3 treatment regimens with Ruxolitinib, 10 mg twice daily (bid), 25 mg bid, or 50 mg once daily (qd). After patients completed 2 cycles of treatment with Ruxolitinib at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis using their discretion in order to achieve an optimal balance of efficacy and safety. During the expansion phase (ie, after optimization of dose), additional patients with PV or ET were enrolled to receive Ruxolitinib at the dose that was selected upon review of data from the dose-ranging phase. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00726232
Study type Interventional
Source Incyte Corporation
Contact
Status Terminated
Phase Phase 2
Start date August 20, 2008
Completion date August 20, 2018

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05115344 - Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors Phase 1
Recruiting NCT05153343 - Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative Phase 1/Phase 2
Completed NCT04243122 - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Phase 2